Taking weed before exercise boosts your motivation, says research. Picture Getty
Weed Week: Hey stoners, exercise is even better on weed; and recent ASX pot winners
Health & Biotech
share
- Taking weed before exercise boosts your motivation, says research
- More Aussie seniors are looking at med cannabis as alternative treatments
- And we take a look at best recent performing pot stocks
Good news for health nuts out there wanting to get more kick out of their sessions.
A study of 42 runners published in the journal Sports Medicine concluded that a bit of weed before a workout can boost motivation, and thus make exercise more enjoyable.
The findings held true regardless of whether participants used THC or CBD-dominant products, although CBD users seem to get more fun out of their exercise.
Participants reported greater enjoyment and more intense euphoria, or “runner’s high,” when exercising after using cannabis.
But for more serious athletes where performance is the goal, it may be best to skip the joint, the study said.
In summary, participant told researchers at the University of Colorado Boulder that weed consumption before exercising:
- Increases enjoyment (91%)
- Decreases pain (69%)
- Increases focus (60%)
- Increases motivation (57%)
- Makes time go by faster (45%)
“Our findings suggest that, among individuals who have experience using cannabis with exercise, smoking or vaporising cannabis flower prior to exercise may lead to increases in both positive (e.g., affect, enjoyment) and negative (e.g., exertion) aspects of the exercise experience,” said the study.
“Participants reported significantly more enjoyment during their cannabis (vs non-cannabis) exercise appointment.”
The findings are somewhat surprising, because it bucks the long-held stereotype that associate cannabis with a couch-bound stoner.
Instead of a couch lock, a very intriguing question has now emerged from the study: Could cannabis actually get people to move more?
Not only Gen-Z, Aussie seniors also looking to cannabis
Meanwhile back home, 1 in 5 Aussies considered or were given a medical cannabis prescription within the last 12 months.
The survey, which was conducted by biotech firm Medigrowth, also noted that 38% of Australians are acquainted with someone using medical cannabis, a figure that rises to 52% among Gen-Z Aussies.
Adam Guskich, CEO and co-founder of Medigrowth, believes the landscape of health discussions in Australia is evolving.
“We’ve observed a substantial rise in prescriptions and an expanding network of GPs prescribing medical cannabis, which indicates a broader acceptance and curiosity about its potential benefits,” Guskich said.
Guskich also noted a shift in the over-65 demographic, with more seniors looking at cannabis as an alternative treatment for conditions such as arthritis, chronic pain and Alzheimer’s disease.
“For seniors in Australia exploring medical cannabis, initiating an open conversation with local healthcare professionals is crucial,” said Guskich.
To ASX Weed Stocks ….
Here’s how the ASX weed stocks have performed, sorted by winners over the past month
| Code | Company | Price | % Week | % Month | % 6-Month | % Year | Market Cap |
|---|---|---|---|---|---|---|---|
| NTI | Neurotech Intl | 0.103 | 13.89 | 38.51 | 105.00 | 60.16 | $89,238,859 |
| ALA | Arovella Therapeutic | 0.150 | 0.00 | 20.00 | 222.58 | 383.87 | $133,171,321 |
| ECS | ECS Botanics Holding | 0.026 | 18.18 | 15.56 | 13.04 | -3.70 | $27,668,267 |
| AVE | Avecho Biotech | 0.004 | 14.29 | 14.29 | -33.33 | -66.67 | $12,677,188 |
| DTZ | Dotz Nano | 0.170 | 6.25 | 6.25 | -8.11 | -27.66 | $85,881,527 |
| LV1 | Live Verdure | 0.400 | 0.00 | 5.26 | 370.59 | 142.42 | $47,698,622 |
| WNX | Wellnex Life | 0.025 | 8.70 | 4.17 | -37.57 | -51.34 | $25,991,414 |
| AGH | Althea Group | 0.038 | -2.56 | 2.70 | -11.63 | -26.92 | $15,049,670 |
| AC8 | Auscann Grp Hlgs | 0.040 | 0.00 | 0.00 | 0.00 | 0.00 | $17,621,884 |
| BOD | BOD Science | 0.024 | 0.00 | 0.00 | -72.41 | -71.76 | $4,256,124 |
| BOT | Botanix Pharma | 0.190 | 11.76 | 0.00 | 26.67 | 227.59 | $297,053,101 |
| CGB | Cann Global | 0.021 | 0.00 | 0.00 | 0.00 | 0.00 | $5,614,845 |
| EPN | Epsilon Healthcare | 0.024 | 0.00 | 0.00 | 9.09 | -4.00 | $7,208,496 |
| EVE | EVE Health Group | 0.001 | 0.00 | 0.00 | 0.00 | 0.00 | $5,274,483 |
| MDC | Medlab Clinical | 6.600 | 0.00 | 0.00 | 0.00 | -5.71 | $15,071,113 |
| ROO | Roots Sustainable | 0.007 | 0.00 | 0.00 | 40.00 | -70.83 | $1,124,217 |
| RNO | Rhinomed | 0.029 | 11.54 | -3.33 | -52.46 | -69.47 | $8,316,471 |
| LGP | Little Green Pharma | 0.140 | 3.70 | -3.45 | -28.21 | -47.17 | $42,013,053 |
| HGV | Hygrovest | 0.048 | -2.04 | -4.00 | -2.04 | -31.43 | $9,463,977 |
| VIT | Vitura Health | 0.240 | -2.04 | -4.00 | -48.39 | -55.56 | $138,209,709 |
| ZLD | Zelira Therapeutics | 0.870 | 0.58 | -5.43 | -45.79 | -28.69 | $10,212,440 |
| WOA | Wide Open Agricultur | 0.150 | 3.45 | -6.25 | -53.85 | -26.83 | $26,853,513 |
| IDT | IDT Australia | 0.097 | -7.62 | -7.62 | 40.58 | 25.97 | $35,147,947 |
| EMD | Emyria | 0.050 | -1.96 | -9.09 | -47.53 | -83.75 | $18,698,099 |
| MXC | Mgc Pharmaceuticals | 0.430 | 22.86 | -10.42 | -85.67 | -95.70 | $17,979,169 |
| CAN | Cann Group | 0.080 | 1.27 | -17.53 | -36.00 | -57.56 | $33,066,461 |
| BP8 | Bph Global | 0.002 | 50.00 | -25.00 | -25.00 | -88.61 | $3,671,126 |
| WFL | Wellfully | 0.003 | -25.00 | -25.00 | -25.00 | -80.00 | $1,478,832 |
| EXL | Elixinol Wellness | 0.010 | 0.00 | -28.57 | -16.67 | -61.54 | $6,328,716 |
| IRX | Inhalerx | 0.020 | 0.00 | -28.57 | -48.72 | -63.64 | $3,795,339 |
| ME1 | Melodiol Glb Health | 0.013 | -23.53 | -35.00 | -93.50 | -96.75 | $3,664,307 |
| EOF | Ecofibre | 0.097 | -3.00 | -35.33 | -52.68 | -56.89 | $36,750,768 |
Neurotech provided an update on the progress of the 11 autism spectrum disorder (ASD) patients who were part of the company’s world-first Phase 1/2 clinical trial.
The trial originally examined the daily use of Neurotech’s proprietary broad spectrum cannabinoid drug therapy, NTI164, out to 52 weeks of treatments.
All patients have now crossed 90 weeks of daily oral therapy with NTI164.
Results show that NTI164 continues to exhibit a safety and tolerability profile, with all patients showing stable blood chemistries and normal liver and kidney function over 90 weeks.
Although no further quantitative efficacy analysis has been collected since week 52, caregiver and clinician reports remain positive with symptomatic improvement maintained at the 90-week mark.
The trial was the longest ever study in ASD, examining the safety of a broad spectrum cannabinoid drug treatment
Data from this trial will support future regulatory interactions and filings for NTI64.
Arovella has entered into a global, exclusive licence with University of North Carolina Lineberger Comprehensive Cancer Center to incorporate the novel armouring cytokine technology (IL-12-TM) for its CAR-iNKT cell platform.
The technology was developed by Professor Gianpietro Dotti, a pioneer of CARiNKT cells, and was recently published in the prestigious peer-reviewed journal Nature Communications.
When the IL-12-TM technology was tested on mice with neuroblastoma, and the mice were assessed four weeks after dosing, investigators found that CAR-iNKT cells containing IL-12-TM were at much higher numbers in the bloodstream (>10 times) than CAR-iNKT cells that did not contain IL-12.
Investigators also found that approximately 75% of the mice were still alive 60 days after treatment for the IL-12-TM group, while all mice in the group treated with CAR-iNKT cells lacking IL-12 had died.
ECS has secured a $9 million offtake agreement with UK-based Rokshaw for supply of medicinal cannabis dried flower over three years.
The supply will commence this financial year with a minimum order volume of 600kg per annum. ECS has also granted Rokshaw a UK market exclusivity of three strains of GMP medicinal cannabis dried flower.
Wellnex entered into an exclusive distribution agreement with Elysian Pharmaceuticals to commence sales of its medicinal cannabis brand, Wellness Life, into the New Zealand market.
Wellnex anticipates commencing supply to Elysian in Q3 this year, subject to relevant regulatory approval which is anticipated to take between four and six months.
Elysian Pharma is an established pharmaceutical and nutraceutical brand and distribution platform in New Zealand, with its medicinal cannabis subsidiary, CannaPlus, servicing over 6,000 patients in 2023.
Meanwhile, the brand Wellness Life is part of a joint venture between Wellnex, Chemist Warehouse and OneLife Botanicals that will also be launched for the growing SAS-B (Special Access Scheme Category B) market in Australia.
Through the SAS-B category, a medical practitioner in Australia is allowed to prescribe a medicinal cannabis product to a single patient.
Explore More
Read MoreCannabis
